Rheumatoid Arthritis accounted for an 18.9% share of the global clinical trials within the Immunology therapy area in 2020, registering a decrease of 4.4% when compared with the last ten-year average of 23.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Rheumatoid Arthritis
Industry sponsored trials held a 61.1% share of all the clinical trials for Rheumatoid Arthritis indication in 2020, registering an increase of 2.7% when compared with the ten-year average of 58.4%. Non-industry sponsored trials accounted for a 38.9% share in 2020, marking a decrease of 2.7% over the ten-year average of 41.6%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Rheumatoid Arthritis trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Rheumatoid Arthritis trials, accounting for a 62.1% share in 2020, when compared with the five-year average of 58.2% and ten-year average of 49.0%.
Europe was at the second position with a 28.4% share in 2020, over the five-year average of 36.4% and ten-year average of 44.9%, followed by North America with a 20.0% share in 2020, as against five-year and ten-year averages of 26.2% and 32.5% respectively.
South and Central America stood fourth with a 5.3% share in 2020, compared with the five-year average of 9.5% and ten-year average of 13.0%, followed by Middle East and Africa with a 3.2% share in 2020, over five-year and ten-year averages of 7.9% and 10.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Rheumatoid Arthritis trials, accounting for a 47.4% share in 2020, as against the five-year average of 26.1% and ten-year average of 15.3%.
The US held a 17.9% share in 2020, over the five-year average of 22.5% and ten-year average of 28.9%, followed by Germany with an 11.6% share in 2020, compared with the five-year and ten-year averages of 15.8% and 16.3% respectively.
Poland held an 8.4% share in 2020, as against the five-year average of 15.5% and ten-year average of 16.6%.
Bulgaria held a 7.4% share in 2020, over the five-year and ten-year averages of 10.0% and 9.8% respectively.
Top regions of non-industry sponsored Rheumatoid Arthritis trials
Asia-Pacific was the top region for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 47.5% share in 2020 when compared with the five-year average of 55.7% and ten-year average of 52.2%.
Europe was at the second position with a 35.6% share in 2020, over the five-year and ten-year averages of 23.4% and 27.3% respectively, followed by Middle East and Africa with a 10.2% share in 2020, as against the five-year average of 11.5% and ten-year average of 9.8%.
North America stood at the fourth position with a 5.1% share in 2020, compared with the five-year average of 9.7% and ten-year average of 10.8%, followed by South and Central America with a 1.7% share in 2020, over the five-year and ten-year averages of 1.8% and 1.8% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 20.3% share in 2020, as against the five-year average of 17.1% and ten-year average of 12.7%.
The Netherlands held a 13.6% share in 2020, over the five-year average of 3.8% and ten-year average of 5.3%, followed by Japan with a 10.2% share, compared with the five-year and ten-year averages of 18.0% and 25.4% respectively.
India held an 8.5% share in 2020, as against the five-year average of 15.1% and ten-year average of 9.7%.
France held a 6.8% share in 2020, over the five-year average of 3.6% and ten-year average of 4.2%.
Phase I trials lead industry sponsored clinical trials for Rheumatoid Arthritis in 2020
Phase I trials held a 65.7% share of industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 50.5% and ten-year average of 43.4%.
Phase IV trials held a 12.1% share in 2020, as against the five-year average of 15.3% and ten-year average of 19.3%. Phase II trials held an 11.1% share in 2020, compared with the five-year and ten-year averages of 16.7% and 18.6% respectively.
Phase III trials held an 11.1% share in 2020, over the five-year average of 17.4% and ten-year average of 18.8%.
Phase IV trials lead non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020
Phase IV trials held a 46.0% share of non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 34.1% and ten-year average of 37.5%.
Phase II trials held a 31.7% share in 2020, as against the five-year average of 46.5% and ten-year average of 46.0%. Phase III trials held an 11.1% share, compared with the five-year and ten-year averages of 12.9% and 11.9% respectively.
Phase I trials held a 11.1% share in 2020, over the five-year average of 6.4% and ten-year average of 4.7%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
